Cargando…

No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients

The influence of treatment with alendronate (ALN), teriparatide (TPTD) or concurrent treatment with both on the human bone matrix mineralization has not yet been fully elucidated. For this purpose we analyzed quadruple fluorochrome labelled transiliac bone biopsy samples (n = 66) from postmenopausal...

Descripción completa

Detalles Bibliográficos
Autores principales: Misof, Barbara M., Roschger, Paul, Zhou, Hua, Nieves, Jeri W., Bostrom, Mathias, Cosman, Felicia, Lindsay, Robert, Klaushofer, Klaus, Dempster, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090359/
https://www.ncbi.nlm.nih.gov/pubmed/32215284
http://dx.doi.org/10.1016/j.bonr.2020.100253
_version_ 1783509916681502720
author Misof, Barbara M.
Roschger, Paul
Zhou, Hua
Nieves, Jeri W.
Bostrom, Mathias
Cosman, Felicia
Lindsay, Robert
Klaushofer, Klaus
Dempster, David W.
author_facet Misof, Barbara M.
Roschger, Paul
Zhou, Hua
Nieves, Jeri W.
Bostrom, Mathias
Cosman, Felicia
Lindsay, Robert
Klaushofer, Klaus
Dempster, David W.
author_sort Misof, Barbara M.
collection PubMed
description The influence of treatment with alendronate (ALN), teriparatide (TPTD) or concurrent treatment with both on the human bone matrix mineralization has not yet been fully elucidated. For this purpose we analyzed quadruple fluorochrome labelled transiliac bone biopsy samples (n = 66) from postmenopausal osteoporotic women with prior and ongoing ALN (ALN-Rx arm) or without ALN (Rx-Naïve arm) after 7 months treatment with cyclic or daily TPTD or without TPTD using quantitative backscattered electron imaging and confocal scanning laser microscopy. Additionally to the bone mineralization density distribution (BMDD) of entire cancellous and cortical compartments, we measured the mineralization kinetics, i.e. the calcium concentration between the younger (Ca_DL2) and older double labels (Ca_DL1), and in interstitial bone (Ca_int) in a subset of the biopsy cohort. We found the BMDD from the patients with prior and ongoing ALN generally shifted to higher calcium concentrations compared to those without ALN (average degree of mineralization in cancellous bone Cn.CaMean + 3.1%, p<0.001). The typical BMDD changes expected by cyclic or daily TPTD treatment due to the increased bone turnover/formation, e.g. an increase in low mineralized bone area were not observed. Additionally, we found no influence of treatment with ALN or TPTD or combination thereof on Ca_DL2, Ca_DL1, or Ca_int. Pooling the information from all groups, Ca_DL1 was +5.9% (p<0.001) higher compared to Ca_DL2, corresponding to a mineralization rate of 0.18 wt% Ca per week during the early secondary mineralization process. Our data suggest that the patients in the ALN-Rx arm had more highly mineralized bone matrix than those without ALN due to their lower bone turnover. The reason for the unexpected BMDD findings in the TPTD treated remain unknown and cannot be attributed to altered mineralization kinetics as no differences in the time course of early secondary mineralization were observed between the treatment groups.
format Online
Article
Text
id pubmed-7090359
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-70903592020-03-25 No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients Misof, Barbara M. Roschger, Paul Zhou, Hua Nieves, Jeri W. Bostrom, Mathias Cosman, Felicia Lindsay, Robert Klaushofer, Klaus Dempster, David W. Bone Rep Article The influence of treatment with alendronate (ALN), teriparatide (TPTD) or concurrent treatment with both on the human bone matrix mineralization has not yet been fully elucidated. For this purpose we analyzed quadruple fluorochrome labelled transiliac bone biopsy samples (n = 66) from postmenopausal osteoporotic women with prior and ongoing ALN (ALN-Rx arm) or without ALN (Rx-Naïve arm) after 7 months treatment with cyclic or daily TPTD or without TPTD using quantitative backscattered electron imaging and confocal scanning laser microscopy. Additionally to the bone mineralization density distribution (BMDD) of entire cancellous and cortical compartments, we measured the mineralization kinetics, i.e. the calcium concentration between the younger (Ca_DL2) and older double labels (Ca_DL1), and in interstitial bone (Ca_int) in a subset of the biopsy cohort. We found the BMDD from the patients with prior and ongoing ALN generally shifted to higher calcium concentrations compared to those without ALN (average degree of mineralization in cancellous bone Cn.CaMean + 3.1%, p<0.001). The typical BMDD changes expected by cyclic or daily TPTD treatment due to the increased bone turnover/formation, e.g. an increase in low mineralized bone area were not observed. Additionally, we found no influence of treatment with ALN or TPTD or combination thereof on Ca_DL2, Ca_DL1, or Ca_int. Pooling the information from all groups, Ca_DL1 was +5.9% (p<0.001) higher compared to Ca_DL2, corresponding to a mineralization rate of 0.18 wt% Ca per week during the early secondary mineralization process. Our data suggest that the patients in the ALN-Rx arm had more highly mineralized bone matrix than those without ALN due to their lower bone turnover. The reason for the unexpected BMDD findings in the TPTD treated remain unknown and cannot be attributed to altered mineralization kinetics as no differences in the time course of early secondary mineralization were observed between the treatment groups. Elsevier 2020-02-27 /pmc/articles/PMC7090359/ /pubmed/32215284 http://dx.doi.org/10.1016/j.bonr.2020.100253 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Misof, Barbara M.
Roschger, Paul
Zhou, Hua
Nieves, Jeri W.
Bostrom, Mathias
Cosman, Felicia
Lindsay, Robert
Klaushofer, Klaus
Dempster, David W.
No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients
title No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients
title_full No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients
title_fullStr No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients
title_full_unstemmed No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients
title_short No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients
title_sort no evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090359/
https://www.ncbi.nlm.nih.gov/pubmed/32215284
http://dx.doi.org/10.1016/j.bonr.2020.100253
work_keys_str_mv AT misofbarbaram noevidenceforalterationinearlysecondarymineralizationbyeitheralendronateteriparatideorcombinationofbothintransiliacbonebiopsysamplesfrompostmenopausalosteoporoticpatients
AT roschgerpaul noevidenceforalterationinearlysecondarymineralizationbyeitheralendronateteriparatideorcombinationofbothintransiliacbonebiopsysamplesfrompostmenopausalosteoporoticpatients
AT zhouhua noevidenceforalterationinearlysecondarymineralizationbyeitheralendronateteriparatideorcombinationofbothintransiliacbonebiopsysamplesfrompostmenopausalosteoporoticpatients
AT nievesjeriw noevidenceforalterationinearlysecondarymineralizationbyeitheralendronateteriparatideorcombinationofbothintransiliacbonebiopsysamplesfrompostmenopausalosteoporoticpatients
AT bostrommathias noevidenceforalterationinearlysecondarymineralizationbyeitheralendronateteriparatideorcombinationofbothintransiliacbonebiopsysamplesfrompostmenopausalosteoporoticpatients
AT cosmanfelicia noevidenceforalterationinearlysecondarymineralizationbyeitheralendronateteriparatideorcombinationofbothintransiliacbonebiopsysamplesfrompostmenopausalosteoporoticpatients
AT lindsayrobert noevidenceforalterationinearlysecondarymineralizationbyeitheralendronateteriparatideorcombinationofbothintransiliacbonebiopsysamplesfrompostmenopausalosteoporoticpatients
AT klaushoferklaus noevidenceforalterationinearlysecondarymineralizationbyeitheralendronateteriparatideorcombinationofbothintransiliacbonebiopsysamplesfrompostmenopausalosteoporoticpatients
AT dempsterdavidw noevidenceforalterationinearlysecondarymineralizationbyeitheralendronateteriparatideorcombinationofbothintransiliacbonebiopsysamplesfrompostmenopausalosteoporoticpatients